Renal cell adenocarcinoma
MONDO:0005549A carcinoma arising from the renal parenchyma. There is a strong correlation between cigarette smoking and the development of renal cell carcinoma. The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass. A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes. Radical nephrectomy is the standard intervention procedure. Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.
Also known as: renal cell carcinoma, RCC, adenocarcinoma of kidney, adenocarcinoma of the kidney, carcinoma, renal cell, malignant, kidney adenocarcinoma, renal cell adenocarcinoma, renal cell cancer
3016 clinical trials for this condition and its sub-types, 98 tagged with Renal cell adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Renal cell adenocarcinoma
-
Clear cell renal carcinoma 140 trials · 142 incl. sub-types
2 sub-types
-
Papillary renal cell carcinoma 26 trials · 28 incl. sub-types
1 sub-type
-
Childhood kidney cell carcinoma 21 trials
-
Sarcomatoid renal cell carcinoma 15 trials
-
Chromophobe renal cell carcinoma 13 trials
2 sub-types
-
Hereditary renal cell carcinoma 1 trial · 7 incl. sub-types
7 sub-types
- Hereditary clear cell renal cell carcinoma 4 trials
- PAX6-related ocular dysgenesis 0 trials · 2 incl. sub-types Sub-types →
- Hereditary papillary renal cell carcinoma 2 trials
- Adrenocortical carcinoma, hereditary 0 trials
- Aniridia 2 0 trials
- Aniridia 3 0 trials
- Renal cell carcinoma, Xp11-associated 0 trials
-
Tubulocystic renal cell carcinoma 0 trials
Most studied deeper sub-types
-
Old drug, new hope: mercaptopurine tested against rare cancer syndrome
Disease control Not yet recruitingThis trial tests the drug mercaptopurine in people with hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic condition that raises the risk of skin, uterine, and kidney tumors. The study aims to find the safest dose and see if the drug can shrink kidney canc…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Immunotherapy after kidney surgery may delay cancer return in rare kidney cancer
Disease control Not yet recruitingThis phase III trial compares the immunotherapy drug pembrolizumab to active surveillance (no treatment) after kidney cancer surgery in patients with non-clear cell renal cell carcinoma, a less common type of kidney cancer. The goal is to see if pembrolizumab can help the immune …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Could a probiotic boost a cancer drug? new trial tests the combo
Disease control Not yet recruitingThis phase 2 trial tests whether adding a probiotic capsule (MO-03) to the drug zanzalintinib can help treat metastatic kidney cancer that has worsened after immunotherapy. About 34 adults with advanced clear cell renal cell carcinoma will receive both treatments. The goal is to …
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New biosimilar aims to offer cheaper option for colorectal cancer
Disease control Not yet recruitingThis Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…
Phase 1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a 5-Day diet boost kidney cancer treatment?
Disease control Not yet recruitingThis study tests whether adding a 5-day fasting-mimicking diet (low-calorie, low-protein) to the usual combination of toripalimab (an immunotherapy) and axitinib (a targeted drug) can help people with advanced kidney cancer. The trial will enroll 43 adults who have not had prior …
Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Cold sore virus modified to fight kidney cancer in new trial
Disease control Not yet recruitingThis phase 2 trial tests a combination of RP2 (a modified herpes simplex virus that targets and destroys tumor cells) and tivozanib (a drug that blocks tumor blood vessel growth) in 35 patients with metastatic kidney cancer that worsened after immunotherapy. The goal is to see if…
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC